treasures of aztec free

treasures of aztec free Why cranberry sauce is America’s least favorite Thanksgiving dish – and 5 creative ways to use it

Harry and Meghan’s polo docuseries to highlight ‘grit behind the glamour’

MUNICH (AP) — Harry Kane is the quickest player to score 50 goals in the Bundesliga after scoring a hat trick on his 43rd appearance on Friday. Kane’s three goals – including two penalties – gave Bayern a 3-0 win over Augsburg , stretching the Bavarian powerhouse’s lead to eight points ahead of the rest of the 11th round. Javascript is required for you to be able to read premium content. Please enable it in your browser settings., , , even have all put their own spin — literally — on a moment from "Wicked. " The choreography from “What Is This Feeling?” is being re-created all over social media, and the trend doesn’t seem to be slowing down. “It’s blowing my mind,” Christopher Scott, the film’s choreographer, tells TODAY.com. Now, Scott is helping viewers with their dancing skills. He recently on how to perform the breakdown from the song's outro, recognized by the repeated refrain of "loathing." The musical sequence, and p , sees Glinda (Ariana Grande) and Elphaba (Cynthia Erivo) express the depths of their disdain for each other during their early days at Shiz University. In the dance flooding TikTok, Glinda — then known as Galinda — marches with her school pals flanked behind her. Scott says it was one of the first group scenes filmed, as the movie was primarily choreographed in sequential order. When he initially showed the moves to his team of dancers, they loved it. Grande gave her blessing, too, he says. “She was like, ‘Oh, my God!’ That was one of the first things she’s seeing of the work — which was pressure on me, because I want her to feel taken care of in this film," he says. "So if she thinks the choreography is not strong, and she’s a part of it, it can mess with people. So it’s important to deliver for them." The dance is meant to physically invoke feelings of frustration, he says. The 25 seconds of viral choreography comes at the very end of the song, as Glinda and Elphaba's "loathing" reaches a fever pitch. “They’re slapping on the books. The way that they twist their body, because they’re irritated by this woman. The thought of Elphaba is making them cringe,” Scott says of the sharp, staccato dance moves. "Wicked" is filled with memorable dance sequences, including the , in which Glinda and Elphaba finally move from enemies to friends. So why did section go so viral? “I think a big part of it is because it came from a place of being connected to the music,” Scott says. “I do think that tapping on the books gave a rhythm for people to become kind of musicians. And I think that level of fun is all part of it. "When you're watching it, it’s like, 'I want to play in that space. I want to be one of those people in Glinda’s crew. And I want to become a part of the movie,'" he adds. One of Scott’s favorite interpretations that he’s seen so far has fittingly The stage musical that inspired the 2024 and 2025 films has been running at the Gershwin Theatre since 2003 and Mary Kate Morrissey as Elphaba and Alexandra Socha as Glinda. “Watching them re-create the choreography from the film that was a re-creation of what they created made me feel like I’m part of the family of ‘Wicked’ and not just the outsider that got to do the film,” Scott says. Scott started working with "Wicked" director Jon M. Chu 15 years ago, including most recently on 2021's "In the Heights," based on Lin-Manuel Miranda's musical of the same name. Scott choreographed the show-stopping number which featured dancers performing styles of dance inspired by Busby Berkeley, ballet, bone-breaking and more — all in a swimming pool. Scott recalls the memorable way Chu asked him to be a part of "Wicked." In March 2022, Chu surprised Scott with a hat from the Broadway musical and said, “You ready to choreograph 'Wicked'?” Then it was time to get to work on the monumental task at hand, Scott says. Here's how he pulled off some of the film's most memorable dance sequences. Scott says he leaned into each actors’ strengths. For instance, once he learned Jonathan Bailey, who plays Fiyero, did gymnastics as a kid, Scott incorporated the actor's exceptional front walkover into the introduction of “Dancing Through Life.” That number, set in a library at Shiz University, features a physical wheel, known as a tornado wheel, that the actors dance on, slide off, climb up and more throughout the song. “There was actually a question on whether or not they were going to let the actors in the space, because for insurance purposes," Scott says. For , Scott used the actor's existing climbing skills from starring in Broadway's "SpongeBob SquarePants" in the "Dancing Through Life" choreography. "If (Slater) auditioned as a performer going into the tornado wheel, he would have booked the job," he says. "It’s very rare you have an actor that can do all of that stuff, to music and the timing." "Dancing Through Life" smoothly transitions into a party scene set off-campus at the "scandalocious" Ozdust Ballroom. While Glinda and Fiyero dance the night away, Elphaba arrives wearing a pointy black hat that Glinda had encouraged her to wear, becoming the laughingstock of the party. Putting on a false confidence, Elphaba starts to dance alone in the middle of the room, before Glinda hesitantly joins her, learning the moves as they go. And with the popular girl's buy-in, the rest of the attendees start dancing, too. The secret sauce for the scene was to not teach the dancers the choreography that Elphaba and Glinda do in the center of the dance floor to make the moment feel organic. “I want to make it believable. I hate when a movie in five seconds, someone does a move and everyone knows the move,” he says. Erivo had been practicing the choreography for days. Grande, however, was introduced to it briefly. “We taught her a very little bit of the movement. Then we just follow along. And she just went with it,” Scott says. For those wondering, yes, it is indeed Jeff Goldblum tap dancing before his song “A Sentimental Man.” “He knows how to tap. He’s a jazz musician. He’s a mover. That man is musically brilliant. I have video. It’s one of my favorite things I own, and I am going to keep it in my little vault,” Scott says. To first learn just Goldblum could move, Scott put on a Frank Sinatra track and freestyled with Goldblum in the room. “‘You got to give the people — rat-a-tat-a-tat — what they want.’ That’s him (tapping)," Scott says of Goldblum's mini song and dance at the Emerald City palace. "We got to set the record straight. And that’s him behind the curtain,” Scott adds. “That is 100% Mr. Goldblum, national treasure at its finest, dancing his face off.”

Ed Cooley Calls Illinois a 'Bulls--t' School, Basketball HC Underwood Reacts in Video

Nuggets rip Lakers, Bucks win as Spurs beat Warriors

By Conor Roche A familiar face for Celtics fans is on the cover of the latest edition of Men’s Health magazine. Celtics star Jaylen Brown donned the cover of Men’s Health ‘s Winter 2024 issue. Brown, who was shirtless on the cover, spoke with Men’s Health fitness director and certified trainer Ebenezer Samuel for the cover story, which was titled “Jaylen Brown vs. the NBA, Nike, and the World.” In the story, Brown shared some of his offseason workouts with Samuel. He also shared some basketball-related thoughts, who his heroes are, and disclosed new information about his relationship with Nike. Here are four things we learned about Brown from the Men’s Health profile, which can be read here . Jaylen Brown on the cover of Men’s Health https://t.co/HFCMv8Gnby pic.twitter.com/URMnvDv8hP Mavericks coach Jason Kidd created some headlines between Games 1 and 2 of the NBA Finals in June, calling Brown the Celtics’ best player. Kidd’s comment was viewed as a tactic to possibly create a divide by some with the Celtics getting a strong victory in Game 1 en route to their Finals win. At the time, Brown said he had “no reaction” to Kidd’s comment. After winning Finals MVP, Brown was asked about Kidd’s comment again by Samuel. “If you ask him, I think he meant exactly what he was saying,” Brown replied. “I think he honestly believed that was just his opinion.” Brown had a strong performance in Boston’s five-game victory over Dallas. He scored 20.8 points per game to go with 5.4 rebounds, five assists, and 1.6 steals per game in the series. But his greatest impact arguably came on the defensive end, where he was the Celtics’ primary defender on Luka Doncic. The Mavericks star shot just 40.9 percent from the field and 25 percent from distance while committing five turnovers when Brown guarded him, per NBA.com’s tracking stats. Kidd and Brown have also developed a relationship off the court. The duo, who are Cal alums, formed a partnership in August to bring XChange to Oakland. Brown formed Boston XChange with help from Jrue and Lauren Holliday earlier in the summer to help “empower underrepresented creators and entrepreneurs by providing the resources, support, and opportunities needed to thrive.” For much of his career, Brown has played second fiddle to Jayson Tatum on the Celtics. Ever since Kyrie Irving’s departure in the 2019 offseason, Tatum has led the team in scoring with Brown finishing second in the team in scoring in each of the last four years. As a result, Tatum has seemed to receive a greater share of the limelight than Brown. Comments like the one Kidd made during the Finals were also frequent before they won a title as some analysts felt Brown was good enough to lead his own team or thought the partnership between him and Tatum wouldn’t work. Brown told Samuel there were times when he thought he should be getting more than what he got in Boston. “I’ve always had the understanding of a process, of a team, and I never really complained about it,” Brown said. “Have I thought I deserved more at certain points in my career? One thousand percent.” Brown didn’t specify what “more” meant in the interview. He had been the subject of trade rumors, though, in recent years, most notably being rumored as the centerpiece of a deal to acquire Kevin Durant in 2022. Obviously, the Celtics kept Brown. They later signed him to a supermax extension in the 2023 offseason that was the largest contract in NBA history at the time, which was surpassed by the extension Tatum signed in July. Now, Brown seems more secure in his role, telling Samuel that he’s “the leader of this team.” “It’s my job to bring the best out of everybody,” Brown told Samuel. “Sometimes it’s okay to take a back seat in order for other people to shine.” Brown told Samuel that he wants to have a legacy akin to the likes of Bill Russell, Muhammad Ali, and Kobe Bryant. “Bill Russell, for what he spoke towards in terms of inequalities and justice for people of color,” Brown told Samuel. “Muhammad Ali, for his belief system, his faith, his charisma, his fearlessness — and his affirmation that ‘I’m the greatest.’ Kobe had that I-don’t-give-a-[expletive] attitude. Kobe’s confidence was real fulfilling, like he really thought that highly of himself — but also because he worked hard.” Brown has often shared his admiration for Russell, a Celtics icon. He was actually tardy for a Celtics practice so he could attend and speak at the City of Boston’s ceremony in renaming the North Washington Street Bridge after Russell in October. “Bill Russell transcends sports,” Brown said at the event . “I can speak on and on about his résumé, but his character, his demeanor, and how he handled himself through adversity, I think that speaks volumes, especially in a time like today. I think it’s very fitting that the bridge is getting named after him, because what a bridge does is bring people together. And the leadership of sports and the role that sports play in our society is bringing people together.” Brown has also been vocal in spreading awareness of off-court issues, similar to Russell. He drove from Boston to Atlanta to be a part of a protest at the height of the Black Lives Matter movement in 2020. He’s also started off-court initiatives, like the aforementioned Boston XChange, to help reduce wealth inequality. Prior to the interview with Samuel, Brown hadn’t shared too much about his admiration for Ali and Bryant in the past. He actually has a tie to Ali, who his grandfather said he boxed against in training sessions . Brown boxed with his grandfather during the NBA’s shutdown in 2020 to remain in shape. But Brown has also spoken a lot about his faith in recent years, observing Ramadan late in the Celtics’ season on multiple occasions. He also performed Umrah as he made the pilgrimage to Mecca, Saudi Arabia, with former Celtics teammate Tacko Fall in July. Ali was also Muslim, converting to Sunni Islam during his boxing career. As for his admiration for Bryant, Brown actually mentioned the Lakers icon as one of the inspirations for why he started 741, his performance brand, in an interview with Stephen A. Smith in October. “A lot of the reason why I started this shoe company is because I read an article around 2019 or so that Kobe was doing the same thing before he passed,” Brown told Smith . On the court, Brown and Bryant have some similarities. Before leading the Lakers to titles in 2009 and 2010, Bryant was also the second fiddle of a two-star tandem with Shaquille O’Neal. Bryant and O’Neal helped the Lakers win three championships in a row from 2000-02 before their falling out led to O’Neal being traded in 2004. Brown’s beef with Nike following his Olympics snub over the summer was one of the bigger storylines surrounding the Celtics after their title win. But he actually negotiated a shoe deal with Nike, along with Under Armor and Puma, after his deal with Adidas expired in 2021, according to Samuel. There was one hold-up that Brown had with Nike and each apparel brand he negotiated with, though, claiming none of them would allow him to design his own signature shoe. “They wasted my time,” Brown said. “They pretended that they would listen. Once it gets to the contract, they’re like, ‘Well, our superstars that we have here that are — that at the time were bigger than I was — this is the contract they have.’” Brown told Samuel that his approach in negotiations probably cost him “millions of dollars worth of deals.” He opted to launch 741 ahead of the Celtics’ regular season, releasing his first signature shoe, the Rover, shortly after. In September, Brown told reporters that he’s hoping the launch of 741 will help inspire other star athletes to do something similar. “My whole ideology is being able to create other options,” Brown said. “There’s a lot of guys who feel like they want to do other things, and they’re afraid, or don’t know how. As a Player’s Association rep, I listen to them. I listen to guys’ stories as they get older. I listen to guys’ stories as they transition through their career and they wish they had other options. “So, the solution for me was to start using my platform to create [those], spark others, and show them exactly how they can do it.” Sign up for Celtics updates🏀 Get breaking news and analysis delivered to your inbox during basketball season. Be civil. Be kind.Panthers rookie tight end Ja'Tavion Sanders released from hospital after suffering neck injuryMinistry eyes digital GDP growth of 5.7%

NoneBLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)(NAPSI)—The holidays are the most wonderful time of the year, but when the average American is spending nearly $1,000 on gifts, food, and decorations, they can also be the most stressful. For many, the pressure to create a picture-perfect holiday can stretch budgets a bit too far. Many of today’s shoppers seek advice from their favorite online influencers, sourcing creative hacks, recipes, DIY projects, and tips to keep the holidays magical without overspending. In fact, 69% of consumers say they value and actively seek out influencer recommendations. Now, questions don’t need to get buried in the comments. This December, TextNow is flipping the script on holiday stress by introducing the Holiday Hotline , a free resource to help you navigate the season, with advice a mere text away. Whether it’s finding affordable gifts, creating a festive dinner on a budget, or even learning how to save on your monthly bills, the Holiday Hotline can make things simpler, cheaper, and—perhaps most importantly—more joyful. TextNow Holiday Hotline: Expert Advice at Your Fingertips From December 5–10, TextNow’s Holiday Hotline connects you with relatable experts (aka some of your favorite influencers including social media creator and podcast host Remi Cruz, Kayla Savings, and Melissa Weiss) who will share their go-to tips for a budget-friendly holiday. Here’s what you can expect: • Holiday Budgeting 101: Learn simple ways to stretch every dollar and avoid those dreaded post-holiday bills. • Affordable Gift-Giving Ideas: Thoughtful, creative gifts that won’t break the bank. • Festive Decorating on a Dime: Transform your home into a holiday wonderland with budget-friendly hacks. • Stress-Free Holiday Cooking: Recipes and meal-planning tips to impress your guests. Need more advice? Just text the hotline at 310-299-3584, and you’ll get personalized, practical tips sent straight to your phone. Win $1,000 for Your Holiday Dinner As if free expert advice wasn’t enough, TextNow is also giving you the chance to win big this holiday season. Enter the $1,000 Dinner Giveaway for a shot at a $1,000 gift card to cover your holiday expenses—whether it’s for food, gifts, travel, or whatever else makes your season special. Entering is simple: 1.Head to TextNow’s Instagram . 2.Like the giveaway post. 3.Share your best holiday tip in the comments (bonus: share the post to your story for an extra entry). 4.The giveaway runs from December 5-12, with winners announced from December 13-16. Save More This Holiday Season TextNow is more than just a phone service—it’s a way to take control of your budget, not just during the holidays but year-round. • Free Phone Service: Unlimited calling and texting on the nation’s largest 5G network free. No gimmicks, no contracts. • Free Essential Data: Get free data for such essential apps as maps, rideshare, and email when you activate your SIM card. • Additional Flexible Data Plans: Add extra data only when you need it, with hourly, daily, or monthly passes. Getting started with TextNow is easy. Download the app to call and text for free over Wi-Fi or unlock free cellular service with a $4.99 SIM card. Learn More For more details, visit www.TextNow.com . Word Count: 491 Stay Informed: Subscribe to Our Newsletter Today

Production tax credits to 'level the playing field'

Shares of apparel company Lululemon Athletica ( LULU 15.89% ) shot up on Friday after the company provided a solid financial report for its third quarter of 2024 and raised its full-year guidance. As of 3 p.m. ET, Lululemon stock was up 16%. Lululemon's growth and profits were higher than estimates It's been a good earnings season for apparel stocks , generally speaking, but I don't wish to take anything from Lululemon. Its Q3 report was strong, showing a 9% year-over-year increase in revenue, which hit $2.4 billion. For its part, management expected revenue closer to $2.3 billion. The financial report from Lululemon was praised by most in the professional analyst community, with many increasing their price targets for the stock. When this happens, investors tend to pay attention. Lululemon also updated aspects of its full-year guidance, considering Q3 sales were better than expected. Previously, it expected 8% to 9% full-year top-line growth, and now it expects growth to come in at 9%. Management anticipates the bottom-line numbers to be toward the higher end of its previous guidance as well. Lululemon is still looking to the long term In 2022, Lululemon's management laid out a plan to double its revenue by 2026. The plan implied an aggressive 15% compound annual growth rate (CAGR) . But the business is well on track, much to the delight of its shareholders. Revenue for 2024 should be close to $10.5 billion and needs to reach $12.5 billion by 2026. That's less than 10% growth in each of the next two years. In conclusion, Lululemon has a credible management team, and that's important for investors who trust what a company's leadership has to say. Moreover, the management team takes care of its shareholders, as evidenced by just adding $1 billion to its buyback plan . In other words, things are still looking good for Lululemon's business, and the big jump in the stock price today seems justified to me.Latest News | Before West Could Imagine Women as Warriors, India Had Ahilyabai, Lakshmibai, Durgavati: RSS Leader

Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/) Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE AmgenCENTRAL ARKANSAS 92, UNC ASHEVILLE 83, 2OT